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ABSTRACT
Endothelial connexin40 (Cx40) contributes to regulate the structure and function 
of vessels. We have examined whether the protein also modulates the altered growth 
of vessels in tumor models established in control mice (WT), mice lacking Cx40 
(Cx40–/–), and mice expressing the protein solely in endothelial cells (Tie2-Cx40). 
Tumoral angiogenesis and growth were reduced, whereas vessel perfusion, smooth 
muscle cell (SMC) coverage and animal survival were increased in Cx40–/– but not 
Tie2-Cx40 mice, revealing a critical involvement of endothelial Cx40 in transformed 
tissues independently of the hypertensive status of Cx40–/– mice. As a result, Cx40–/–  
mice bearing tumors survived significantly longer than corresponding controls, 
including after a cytotoxic administration. Comparable observations were made in WT 
mice injected with a peptide targeting Cx40, supporting the Cx40 involvement. This 
involvement was further confirmed in the absence of Cx40 or by peptide-inhibition 
of this connexin in aorta-sprouting, matrigel plug and SMC migration assays, and 
associated with a decreased expression of the phosphorylated form of endothelial nitric 
oxide synthase. The data identify Cx40 as a potential novel target in cancer treatment.
INTRODUCTION
Angiogenesis, i.e. the growth of new capillaries 
sprouting from pre-existing blood vessels, is fundamental 
to many physiological and pathological events, including 
tumor survival and growth [1]. The mechanism leading 
to angiogenesis requires the coordinated response of 
endothelial cells (ECs) to multiple stimuli [2], including 
basic fibroblast growth factor, vascular endothelial 
growth factor and nitric oxide (NO), which stimulate the 
proliferation, survival, migration and differentiation of 
ECs [3–5]. As yet, however, such molecules have shown 
modest and transient effects in cancer therapy [6–8], thus 
calling for the identification of novel endothelial targets. 
Connexins (Cx) form channels for the electrical and 
metabolic signaling, which coordinates the functions of 
individual cells [9], notably within the wall of normal blood 
vessels [10–12]. Between ECs, this signaling is mediated by 
Cx40 and Cx37 [13]. The combined invalidation of Cx40 
and Cx37 causes lethal, perinatal hemorrhages, suggesting 
that these 2 proteins are required for the normal development 
of the microvasculature [14]. Cx40-null mice (Cx40–/–) 
also display impaired endothelial-dependent dilation of 
blood-vessels in response to various agents [15, 16], and are 
hypertensive mainly due to increased renin secretion [17–19]. 
We hypothesized that Cx40 may also participate 
in the angiogenic response of tumoral tissues. To test 
this hypothesis, we have compared WT mice, expressing 
control levels of Cx40, with Cx40–/– mice, which lack this 
Cx [20] and with Tie2-Cx40 animals, which specifically 
express Cx40 solely in ECs [21]. We have further studied 
the in vitro and in vivo effect of a peptide which mimics 
extracellular portions of Cx40, and specifically targets 
this protein [22, 23]. The data provide direct evidence that 
Cx40 plays a pivotal role in the control of angiogenesis 
and tumor growth, possibly by reducing NO production. 
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RESULTS
Loss of endothelial Cx40 decreases tumor growth 
and vessels, independently of hypertension
We compared knock-out mice which lack Cx40 and 
transgenic Tie2-Cx40 mice [21], in which this protein is 
solely restored in ECs (Figure 1A). Two weeks after the 
implantation of TC-1 cells into the flank of either WT, 
Cx40–/– or Tie2-Cx40 mice, sizable tumors with capillaries 
expressing Cx40 (Figure 1A) had grown in all WT and 
Tie2-Cx40 mice (Figure 1B). In contrast, smaller tumors 
had grown in Cx40–/– mice (Figure 1B), which exhibited a 
lower hemoglobin content and density of blood vessels than 
the tumors of WT and Tie2-Cx40 animals (Figure 1C–1D). 
The data document that the loss of endothelial Cx40 reduces 
growth and angiogenesis of a subcutaneous (s.c.) tumor.
Comparable observations were made after the 
instillation of TC-1 cells in the bladder of Cx40–/– mice 
(Figure 2A and 2B). In contrast, the native bladders of 
both WT and Cx40–/– mice featured a similar network of 
capillaries (Figure 2C), irrespective of the absence (Cx40–/–) 
or presence (WT; Supplementary Figure S1) of EC Cx40. 
The data show that loss of this protein only alters the 
growth and the angiogenesis of transformed tissues.
Given that Cx40–/– mice are hypertensive [17, 19] 
and that angiogenesis may be influenced by blood pressure 
[24], the experiments were repeated using mice treated with 
Candesartan for 3 weeks. The drug decreased to control 
levels the blood pressure of Cx40–/– mice, without affecting 
the normal blood pressure of WT controls (Supplementary 
Figure S2). Under these conditions, the Candesartan-
treated WT-mice developed bladder-tumors similar to those 
of untreated controls (Figure 2D), whereas Candesartan-
treated Cx40–/– mice developed fewer and smaller tumors, 
similar to those of the untreated hypertensive companions 
(Figure 2D). The data show that loss of Cx40 decreases the 
growth and angiogenesis of bladder tumors by a mechanism 
which is not affected by blood pressure. 
Loss and inhibition of Cx40 decrease 
angiogenesis 
One week after the s.c. implantation of matrigel-
plugs supplemented with heparin and Vascular Endothelial 
Growth Factor (VEGF), an intense red staining and sizable 
hemoglobin content of the plugs, indicating extensive 
angiogenesis, was observed in WT mice (Figure 3A). 
Both parameters were significantly reduced in the 
plugs implanted in Cx40–/– mice (Figure 3A). Parallel 
experiments revealed that supplementing the plugs with 
40Gap27, a peptide known to specifically inhibit Cx40 
function [22, 23, 25], reduced the angiogenesis in WT 
mice, in contrast to plugs supplemented with a scrambled 
version of this peptide (Figure 3A). Comparable 
observations were made with matrigel plugs containing 
Fibroblast Growth Factor (FGF) (Supplementary 
Figure S3). The data demonstrate that interfering with 
Cx40 function reduces the in vivo neo-angiogenesis, 
whichever the angiogenic stimulus tested. This was 
further confirmed by the absence of Vascular Endothelial 
Growth Factor Receptor-2 modulation in TC-1 s.c tumors 
of Cx40–/– mice (Supplementary Figure S4).
After 4 days of culture in matrigel, aorta explants 
from WT mice showed sprouting of capillary-like 
structures, whose ECs co-expressed Cx40 and CD31 
(Figure 3B). This sprouting, which increased for the 7-day 
duration of the experiment (Figure 3C), was significantly 
reduced in explants from both Cx40–/– mice and from WT 
mice exposed to the 40Gap27 peptide (Figure 3C). 
In another set of experiments, primary human ECs 
(HUVECs), were seeded onto matrigel, to form vascular-
like 3D structures [26]. The development and branching 
of these structures, were significantly reduced by addition 
of 40Gap27, but not its scrambled form (Figure 3D). The 
data document that Cx40 increases EC migration, vessel 
sprouting and growth.
The absence of Cx40 improves the perfusion and 
function of tumor-vessels 
After i.v. injection of FITC-labeled tomato lectin 
in tumor-bearing mice, we found that more vessels were 
labeled by the lectin in tumors grown in Cx40–/– than 
WT mice (Figure 4A), indicating increased perfusion of 
tumor vessels lacking Cx40. Immunostaining for smooth-
muscle actin (SMA), further revealed more mural cells 
around the vessels of tumors established in Cx40–/– than in 
WT mice (Figure 4B). This increase was associated with the 
loss of endothelial Cx40, inasmuch as it was not observed in 
the vessels of tumors grown in Tie2-Cx40 mice (Figure 4B). 
The data demonstrate that the absence of Cx40 improved the 
function and structure of tumor vessels. 
Seven, 14 and 21 days after the s.c. implantation of 
TC-1 cells, we i.p. injected WT and Cx40–/– mice with 
cyclophosphamide (CTX). In WT mice, this treatment 
prolonged mice survival (14% of surviving mice at the end 
of the 90 days experiment), as compared to that observed 
for untreated WT mice, which all died within 7 weeks 
(Figure 4C). Under the same conditions, the survival of 
Cx40–/– mice was significantly longer (83% and 36% of 
the mice surviving at the end of the experiment, in the 
presence and absence of CTX administration, respectively 
(Figure 4C). The data show that lack of Cx40–/– extends 
the survival of tumor-bearing mice, especially in the 
presence of a cytotoxic drug.
Inhibition of EC Cx40 promotes the recruitment 
of vascular SMCs and decreases eNOS activation 
In the presence of 40Gap27, an increased recruitment 
of A7r5 SMCs to HUVEC-made vessels was observed 
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Figure 1: Loss of Cx40 decreases the growth and angiogenesis of TC-1 s.c. tumors. (A) Immunostaining of Cx40 showed the 
presence of the connexin at ECs (identified by co-staining for CD31) of tumors which grew in WT and Tie-2-Cx40 mice, but not in those 
which developed in Cx40–/– mice. (B) 14 days after the injection of TC-1 cells, Cx40–/– mice develop s.c tumors of smaller size compared 
to WT and to Tie2-Cx40. Dots represent individual mice; horizontal lines show geometric mean values. (C) The normalized hemoglobin 
content was also similar in the tumors of the Tie2-Cx40 and WT mice, but lower in the tumors of Cx40–/– mice. Data are mean + SEM of 
6 mice per group. (D) Immunostaining of the endothelial specific von Willebrand (vW) factor revealed a similar density of vessels in the 
TC-1 tumors which developed in the Tie2-Cx40 and WT mice, and much lower in the tumors that developed in Cx40–/– mice. Data are 
mean + SEM of 6–7 areas from tumors of similar size that developed in 5 different mice per group. Significant differences are shown as 
*p < 0.05; **p < 0.01; ***p < 0.001 versus WT mice and °p < 0.05; °°p < 0.01 versus Cx40–/– mice.
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(Figure 5A), suggesting that Cx40 signaling negatively 
regulates SMC and/or stromal recruitment to newly 
formed vessels. Western blots further showed that a 4 h 
targeting of Cx40 using 40Gap27, reduced the expression 
of PeNOS, as compared to the levels observed in both 
untreated cells and cells exposed to the scrambled 
peptide, while the expression of other angiogenesis-
related proteins, such as VEGFR2, MMP2, VE-cadherin 
and eNOS was unchanged (Figure 5B). The data document 
that Cx40 decreases eNOS signaling in ECs.
Loss of Cx40 decreases the growth and 
angiogenesis of B16-F10 tumors and reduces 
PeNOS expression
Eleven days after the s.c. implantation of 
B16-F10 melanoma cells, sizable tumors had grown 
in all WT mice (Figure 6A). In contrast, Cx40–/– mice 
developed significantly smaller tumors (Figure 6A), which 
featured a lower hemoglobin content (Figure 6B) and 
vascular density (Figure 6C), but higher levels of SMA 
(Figure 6D). In addition, the expression of PeNOS was 
significantly decreased in the vessels of B16 tumors grown 
in Cx40–/– mice, compared to the levels seen in WT mice 
(Figure 6E and 6F). Comparable observations were made 
in the TC-1 tumors (Supplementary Figure S5). The 
data show that, in the absence of Cx40, the modulation 
of angiogenesis and growth of different tumor models is 
associated to decreased PeNOS expression. 
Targeting Cx40 decreases tumoral angiogenesis 
and growth 
One day after the implantation of either TC-1 
or B16 cells, mice were injected daily i.p. with 100 µg 
40Gap27, which has been reported to inhibit Cx40, 
or its scrambled version. Within 2 weeks, all mice 
injected with 40Gap27 developed significantly fewer and 
Figure 2: Loss of Cx40 decreases growth and angiogenesis independently of hypertension in bladder-tumors. (A) In WT 
mice, the size (top) and weight of the bladders (bottom) was higher in the animals instilled with TC-1 cells than in non instilled controls. 
TC-1-instilled Cx40–/– mice featured bladders with sizes and weights significantly smaller than those seen in the corresponding WT mice, 
Dots represent individual mice; horizontal lines show mean values. Gray area represents the mean weight + 3 SD of native mice bladders. 
(B) Immunostaining for vWF revealed a lower density of vessels in the TC-1 tumors which developed in the bladders of Cx40–/– than 
of WT mice. Data are means + SEM of 4–7 areas from similar size tumors in 3–4 different mice per group. (C) Immunostaining of vWF 
revealed a similar density of vessels in the native bladder of WT and Cx40–/– mice. Data of right panel are mean + SEM values of 3 fields, 
photographed in each of 3 mice per group. (D) The difference in the weights of bladders between WT and Cx40–/– mice instilled with 
TC-1 cells, was not altered by the Candesartan treatment. Dots represent individual mice; horizontal lines show mean values. Significant 
differences are shown as *p < 0.05; **p < 0.01; ***p < 0.001 versus respective WT mice. 
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smaller tumors (Figure 7A–7E), with a less developed 
vascularization (Figure 7B–7C–7F–7G) but an increased 
SMA coverage (Figure 7D–7H), than the mice injected 
with the scrambled peptide. The data show that 
targeting Cx40 with a mimetic peptide recapitulates the 
observations made in Cx40–/– mice. 
DISCUSSION
We report that Cx40, one of the prominent proteins 
that, together with Cx37 and Cx43, form gap junctions 
between ECs, participates to control angiogenesis in 
transformed tissues. Using WT, Cx40–/– and Tie2-
Cx40 mice, as well as a peptide known to specifically 
target Cx40, we show that loss of Cx40 is associated 
with decreased angiogenesis in different in vitro, ex vivo 
and in vivo models. We further demonstrate that Cx40 
participates to control the growth of melanoma and uro-
genital tumors in association with changes of tumoral-
vessels, and altered eNOS activity. In the absence of 
Cx40, the newly-formed tumoral vessels also formed 
an almost control wall structure, including a substantial 
coverage of the ECs by many SMCs, which resulted in 
an improved perfusion of the growing tumor, presumably 
accounting for the extended mouse survival observed after 
cyclophosphamide administration. These effects appear 
largely attributable to the Cx40 expressed within the 
vascular endothelium, inasmuch as they were prevented in 
transgenic Tie2-Cx40 mice in which Cx40 was exclusively 
restored in the ECs of Cx40–/– animals [21]. 
Figure 3: Loss of Cx40 attenuates angiogenic potential of ECs. (A) One week after the s.c. injection of matrigel plugs supplemented 
with VEGF, both the red color and the hemoglobin content were found reduced in plugs retrieved from Cx40–/– mice compared to WT 
mice. In WT mice, VEGF matrigel plugs supplemented with a scrambled version of the 40Gap27 peptide resembled the plugs containing 
only VEGF (WT). In contrast, in matrigel plugs prepared with VEGF and the 40Gap27 peptide, both the red color and the hemoglobin 
content were sizably reduced, and resembled those observed in Cx40–/– mice. Data are mean + SEM of 9–15 mice per group. (B) After a 
7 day culture, immunostaining of vessels sprouting out from aortic rings shows the spotted distribution of Cx40 (green spots) on CD31-
identified ECs (red). (C) After a 3 day culture, aortic rings of WT mice show a sizable capillary outgrowth, which increased with culture 
time. This sprouting was reduced in aortic rings of Cx40–/– mice or of WT mice in the presence of the 40Gap27 peptide, which targets Cx40. 
Data are mean + SEM of 10–15 rings from 3–4 mice per group. (D) In vitro, the ability of HUVECS to form capillary-like structures onto 
matrigel was altered in presence of the 40Gap27 peptide. Results are means + SEM from 3 separate experiments performed in triplicate and 
2 different fields per replicate were pictured.
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The mechanism(s) underlying the connexin effects 
remain(s) to be fully unraveled. Knocking down of Cx40 
in HUVECs using specific siRNA, was already shown to 
decrease the formation of capillary-like structures [27]. 
We now document that the absence of Cx40, as well as the 
interference with this connexin, decreases the formation 
of new capillary-like vessels, essentially made of ECs, 
while increasing their recruitment of SMA-positive SMC 
and stromal cells. Under these conditions, VEGF and 
its receptor, which are main inducers of angiogenesis 
[3], were unchanged. In contrast, we document that loss 
of Cx40 decreased the formation of novel vessels, in 
association with a reduction of PeNOS, the activated form 
of the EC enzyme which directly controls the production 
of NO [28, 29], including in Cx40–/– mice [21]. In turn, 
this second messenger increases EC differentiation and 
migration, while inhibiting SMC recruitment [30, 31]. 
Recent experiments have indicated that Cx40 controls the 
expression and function of eNOS [15, 21], possibly by 
decreasing the exchanges of Ca2+ transients between EC 
[16] which modify eNOS activation [32], or by impairing 
the protein complex that Cx40 forms with the enzyme 
[33]. Thus, our data implicate that the relationship between 
Cx40 expression and the production of NO is relevant to 
the control of tumoral angiogenesis.
Immunofluorescence showed that the labeling of 
Cx40 within the ECs of these mice was similar to that 
seen in WT controls. Accordingly, one would expect that 
the angiogenic parameters we evaluated here would also 
be alike in Tie2-Cx40 and WT controls, which is what our 
Figure 4: Cx40 deficiency causes enhanced tumor vessel maturation and functionality. (A) Tomato lectin (green) labeled 
most of the vessels (identified in red by immunostaining for CD31) in tumors grown in Cx40–/– whereas some vessels were not stained 
by lectin in WT mice; white arrows indicate tumor vessels (CD31+) that were not perfused (lectin-). Data are mean + SEM of 8–10 fields 
from 3 different mice per group. (B) Immunostaining of alpha-SMA and CD31 showed the distribution of SMCs and ECs in the vessels of 
TC-1 tumors. The density of co-stained vessels was higher in the tumors induced in Cx40–/– than in those induced in Tie2-Cx40 and WT 
mice. Data are mean + SEM of 3–8 fields from 4–5 different mice per group. *p < 0.05 versus WT mice and °°p < 0.01 versus Cx40–/– 
mice. (C) Cyclophosphamide (CTX) treatment (arrows) of WT mice s.c. injected with TC-1 (n = 7, open circles) significantly prolonged 
mice survival (14% of surviving mice at the end of the 90 days experiment), as compared to WT untreated mice that all died within 7 weeks 
(n = 14; solid circles, p < 0.01). Survival of Cx40–/– mice injected with the same amount of TC-1 cells (n = 14; solid squares) was 
significantly higher than WT mice (36% of surviving mice, p < 0.01). Even more effective, CTX treatment in Cx40–/– mice (n = 6; open 
squares) resulted in 83% of the mice surviving (p < 0.01 as compared to CTX-treated WT mice). Significant differences by a log rank test 
are shown *p < 0.05 or **p < 0.01.
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data indicate. Obviously, the effects which are dependent 
on Cx40 do not rule out the possible concomitant 
involvement of the other EC connexins, whether 
composing gap junction channels or hemi-channels, 
notably because Cx40 oligomerizes with Cx37 in some 
connexons [34], and that loss of Cx40 also reduces the 
expression of Cx37 which has been reported to inhibit 
Cx40 [15, 21, 35, 36]. Furthermore, our findings do not 
exclude either that other more intricate mechanisms could 
contribute to decrease tumoral aniogenesis, including the 
possible activation of an EC-dependent, local immune 
reaction triggered after loss of Cx40, and/or other connexin 
isoforms. Additional mechanisms may be associated with 
the decreased transfer between ECs of Cx40–/– mice [14] 
of gap junction-permeant molecules, such as ATP [37], 
reactive oxygen species, and Ca2+ [16, 21, 38], which are 
all critical mediators for the proper building and function 
of newly formed vessels. Connexin signaling has been 
implicated in the control of many secretions, including 
that of growth factors [39] and renin [9]. By analogy, it 
is plausible that EC Cx40 may control the secretion of 
pro-angiogenic molecules, such as platelet-derived growth 
factor (PDGF), which is necessary for the formation and 
the maturation of newly formed vessels. In many tumors, 
the chronic imbalance of pro- and anti-angiogenic signals, 
notably PDGF, leads to the development of abnormal 
vasculature [1, 40–42] which, in turn, is thought to impair 
the access of drugs and antibodies to several types of 
cancer-cells, presumably contributing to their limited 
sensitivity to therapy [1]. Thus, preservation of a normal 
vascular bed, e.g. by altering the tumor environment, is 
emerging as a necessary complement for improving the 
efficacy of cytotoxic and radiation therapies [1, 43–45], 
and it has been proposed that connexins may participate 
to this improvement [43]. Our data provide evidence that 
this can be actually achieved in tumors models, since 
both the loss and inhibition of Cx40 and its targeting by a 
mimetic peptide markedly extended the survival of tumor-
bearing mice, including during a systemic administration 
of cyclophosphamide.
The findings of such a beneficial effect under 
different settings (several types of tumors growing in 
different environments, explant cultures of a normal 
vessel, in vivo implantation of artificial plugs) does not 
Figure 5: Cx40 inhibition in ECs promotes the recruitment of vascular SMCs. (A) Fluorescent A7r5 SMCs were added in 
wells containing a capillary network of HUVECs. After 6 hours, quantitative assessment of the number of attached SMCs revealed an 
increased recruitment of A7r5 cells when the capillary-like structures were generated under the presence of the 40Gap27 peptide compared 
to its scrambled version. Results are means + SEM from 3 different experiments performed in duplicate. 2–3 pictures per replicate have 
been analyzed. (B) Western blot analysis performed on 2D HUVECs revealed that Cx40 inhibition during 4 hours using the 40Gap27 peptide 
reduces the phosphorylation of eNOS whereas, VEGFR2, MMP2 and VE-cadherin were unaffected. Data shown are means + SEM from 3 
separate experiments performed in triplicate. Significant differences are shown as *p < 0.05; ***p < 0.001 versus Scramble peptide treatment.
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support the view that the connexin effect is dependent on a 
specific cell type or a given host environment. Rather, our 
data indicate that the loss of Cx40 signaling consistently 
decreases the development of neo-vessels, while improving 
their maturation, as judged by the increased coverage of 
ECs by SMA-expressing contractile cells. Strikingly, this 
connexin-dependent effect was evident under conditions 
of actively stimulated angiogenesis in both tumoral and 
non tumoral tissues, but was not observed under the more 
chronic, steady state conditions of control vessels renewal, 
which was presumably the situation in the histologically 
normal regions of the murine bladders we analyzed. If 
validated, this differential effect could largely benefit the 
future therapeutic translation of the experimental approach 
Figure 6: Loss of Cx40 attenuates the growth and angiogenesis of subcutaneous B16-F10 tumors. (A) 11 days after the 
s.c. injection of B16-F10 cells, tumors of smaller size developed in Cx40–/– mice than in WT mice (p < 0.01). Dots represent individual 
mice; horizontal lines show mean values. (B) The normalized hemoglobin content was also lower in Cx40–/– tumors. Data are mean + 
SEM of 8 mice per group (p < 0.001). (C) Immunostaining of vWF revealed a lower density of vessels in the B16-F10 tumors grown in 
Cx40–/– than in WT mice (p < 0.001). Data are mean + SEM of 3–4 areas from 3 different mice per group. (D) Immunostaining of SMA 
and CD31 showed the distribution of SMCs and ECs in the vessels of B16 tumors. The volume density of SMCs was higher in the tumors 
induced in Cx40–/– than in those induced in WT mice (p < 0.01). Bar, 50 µm. Data are mean + SEM of 3–9 fields from 3 different mice per 
group. (E) Immunostaining showed the presence of PeNOS in the CD31 positive ECs of the B16 tumors grown in WT mice. The staining 
for the former molecule was lower in the tumors induced in Cx40–/– than in WT mice (p < 0.001). Data are mean + SEM of 3–6 fields 
from 3 different mice per group. (F) Western blots demonstrated a significant increase in SMA/vWF and SMA/Tubulin (p < 0.05) and a 
significant decrease in in vWF/Tubulin and PeNOS/eNOS (p < 0.05) in tumors grown in Cx40–/– mice. Data are mean + SEM of 6 different 
mice per group. Significant differences are shown as *p < 0.05.
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we describe here. Indeed, since the vessels of human 
tumors express Cx40 (Supplementary Figure S6), a protein 
which shares large homology with mouse Cx40 in the 
extra-cellular region which is targeted by 40Gap27 [46], and 
since loss of Cx40 does not appear to significantly alter the 
microcirculation established in normal adult tissues, our 
findings open the challenging perspective that targeting 
Cx40 may also be useful in the treatment of cancer patients. 
Figure 7: A peptide targeting Cx40 decreases tumoral growth and angiogenesis. (A and E) Two weeks (15 and 13 days 
respectively) after the injection of WT mice with either TC-1 (A) or B16 cells (E), the volume of the resulting tumors was significantly 
lower in the mice which received 40Gap27, than in those which received the scrambled version of the peptide. Dots represent individual 
mice; horizontal lines show geometric (A) and arithmetic (E) mean values. (B and F) the hemoglobin content was also lower in the tumors 
grown in mice treated with 40Gap27 peptide than in those which received the scrambled version of the peptide. (C and G) Immunostaining 
of vWF revealed a lower density of vessels in the tumors grown in mice which received the 40Gap27 peptide. (D and H) Immunostaining of 
SMA revealed a higher density of SMCs in the tumors induced in mice treated with the 40Gap27 peptide. In all bar graphs, data are mean + 
SEM of 3–9 fields from 3 different mice per group. Significant differences are shown as *p < 0.05; **p < 0.01.
Oncotarget14024www.impactjournals.com/oncotarget
MATERIALS AND METHODS
Animals and human samples
8–12 weeks-old female C57BL/6 wild type (WT), 
Cx40–/– [47] and Tie2-Cx40 mice expressing Cx40 solely 
in ECs [21], were used according to the animal procedures 
approved by our institutional and state committees for 
animal experiments, and conform to the Guide for the Care 
and Use of Laboratory Animals (US National Institutes 
of Health, 8th edition, 2011). All transgenic mice were 
maintained on a C57BL/6 background and genotyped by 
PCR [15, 21]. 
The generation of Cx40–/– and Tie2-Cx40 mice 
and their genotypic characterization has been described 
[17, 35]. The Tie2-Cx40 mice used in this study, 
were generated by crossing Tie2-Cx40 heterozygous 
transgenics with C57BL/6-Cx40–/– mice [21]. We have 
previously reported that these animals express Cx40 
only in ECs, at levels that, in individual cells assessed by 
immunofluorescence, appeared alike those of WT controls, 
still in tissue extracts assessed by Western blotting, were 
overall intermediate between those of Cx40–/– and WT 
control mice, presumably because Cx40 expression was 
not induced in all ECs [21]. 
In some experiments, WT and Cx40–/– mice 
received for 3 weeks drinking water containing 3 mg/kg. 
day Candesartan (Cilexetil®, Atacand, Astra Zeneca), 
and blood pressure was monitored by tail cuff 
plethysmography method as previously described 
[21, 35, 48]. Samples of invasive bladder cancers were 
obtained at cystectomies after informed patient consent 
and with the authorization of our state ethical committee 
(study 119/10). 
Tumor models
Two widely used subcutaneous tumor models 
were generated in WT, Cx40–/– and Tie2-Cx40 mice 
using TC-1 cells (human papillomavirus oncogene 
expressing cells derived from C57/Bl6 lung epithelium 
[49] or B16-F10 mouse melanoma cells [50]. Mice were 
(s.c.) injected into the flank with 2 × 104 TC-1 or 2.5 × 
105 B16-F10 cells and tumor-growth monitored every 
two days with a caliper. Tumor volume was calculated as 
length × width2 /2 and mice sacrificed when tumor volumes 
were > 1.25 cm3, according to veterinary guidelines. For 
comparison to healthy organs, orthotopic bladder tumors 
were also generated by intravesically instilling 2.5 × 105 
TC-1 cells into the bladder, as previously described [51]. 
The size of these tumors was estimated by weighing the 
bladders at animal sacrifice. At that time, all tumors were 
frozen into liquid nitrogen. 
In some experiments, 50 mg/kg b.w. cyclophosphamide 
(CTX, C-0768 from Sigma), were intraperitoneal (i.p.) 
injected three times, once a week, for 3 weeks (at days 8, 
15 and 22) into subcutaneous TC-1 tumor-bearing mice [52]. 
In other experiments, WT mice were also i.p. injected every 
day with 100 µg of either 40Gap27 peptide or its scrambled 
version, starting one day after tumor cell implantation. 
The sequence of the 40Gap27 peptide differs by 3 amino 
acids of the fourth transmembrane connexin stretch from 
that of peptide Gap27, which was originally generated to 
inhibit Cx43 [22]. Previous studies have documented that 
40Gap27 does not inhibit Cx43 but specifically targets Cx40 
[23, 25]. The concentrations of the 40Gap27 peptide tested 
in this study were similar to those reported to be effective in 
blocking Cx40 function in previous studies [22, 23, 25].
Matrigel plug assay
Plugs of 0.5 mL Growth Factor Reduced matrigel 
(BD Biosciences, 356231) supplemented with either 
500 ng/ml recombinant murine FGF-2 (Peprotech, 
450–33) and 3 U/ml Heparin (Biochrom AG, L6510) 
or 200 ng/ml recombinant murine VEGF165 (Peprotech, 
450–32) and 10 U/ml Heparin [53], were s.c. injected into 
the flank of either WT or Cx40–/– mice. Matrigel lacking 
growth factors were used as negative control. WT mice 
were also injected with Growth Factor Reduced matrigel 
supplemented with 200 ng/ml VEGF, 10 U/ml Heparin 
and 300 µM of either peptide 40Gap27 or its scrambled 
version. The plugs were removed 1 week after injection, 
for evaluation of vascularization.
Aortic ring assay
Mouse aortas from 10 week-old WT and Cx40–/– 
mice, were cut into rings of 1 mm thickness [54], dropped 
in 20 μl matrigel previously polymerized during 30 min 
at 37°C (BD Biosciences, 356237), and overlaid with 
30 μl matrigel (BD Biosciences, 356237). After another 
30 min polymerization at 37°C, Endothelial Cell Growth 
Medium-2 (Lonza, EGM™-2 BulletKit™, C2517A) 
was added, and then changed every 3 days. In some 
experiments, the assay was performed on aortic rings 
from mice pretreated for 1 week with 100 µg of either 
peptide 40Gap27 [23] or a scrambled version of this 
peptide (Protein and Peptide Chemistry Facility of the 
Institute of Biochemistry, UNIL, Switzerland), and given 
by intraperitoneal (i.p.) injection every two days. Aortic 
rings were then embedded in matrigel supplemented with 
300 µM either peptide 40Gap27 [23] or the scrambled 
peptide. In all cases, vessel sprouts were photographed 
with a bright-field contrast microscope (Nikon Eclipse 
TS100), from day 3 to 10.
Immunostaining 
Ethanol-fixed aortic rings and 8 µm-thick 
cryosections of tissues and tumors were incubated in 
blocking buffer (PBS, 2% BSA, 0.3% Triton X-100) for 
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1 h at room temperature, and then incubated overnight at 
4°C in PBS with one of the following antibodies against: 
CD31 (BD Pharmingen, 553371), diluted 1:100; Cx40 
(Alpha Diagnostic International, Cx40-A), diluted 1:50; 
cleaved VEGFR2 (Cell Signaling Technology, 2479), 
diluted 1:100; Von Willebrand Factor (VW¸Dako, A0082), 
diluted 1:500; Phospho eNOS (PeNOS, Cell Signaling 
Technology, 9571), diluted 1:100; alpha-smooth muscle 
actin (SMA, Abcam, ab5694) diluted 1:100. Samples were 
then incubated for 2 h at room temperature with either 
Alexa-Fluor-594- or -488-coupled secondary antibodies 
(Life Technologies), diluted 1:500 in PBS, covered with 
PBS containing 50% glycerol and 0.4 μg/mL DAPI, and 
observed by fluorescence microscopy (Leica Leitz DMRB, 
Nidau, Switzerland). Frozen sections from human bladder 
biopsies were also stained with hematoxylin and eosin.
Hemoglobin content 
Hemoglobin content was quantified using the 
Drabkin’s reagent kit (Sigma Chemie, Buchs Switzerland). 
Briefly, 100 mg tumor powder or excised matrigel-plugs 
were homogenized in 0.5 mL 0.1% Brij-35 lysis buffer, 
and centrifuged for 5 min at 10`000 g. 50 µL of the 
supernatant was mixed with 450 µL Drabkin's reagent, 
and absorbance read at 540 nm. The concentration of 
hemoglobin was calculated from a cyan-methemoglobin 
standard. 
Tumor perfusion assay
Mice were intravenously (i.v.) injected with 100 μg 
FITC-tomato lectin (Vector, FL-1171, diluted in PBS). 
Five min later, mice were perfused systemically with 4% 
paraformaldehyde through the left heart ventricle, and 
then sacrificed before tumor sampling. Tumor tissues 
were fixed in 4% paraformaldehyde for 2–3 additional 
hours, and incubated in 30% sucrose overnight at 4°C. 
The tissues were then embedded in OCT compound, cut 
at 20 μm thickness and kept frozen at −80°C. CD31 was 
immunostained as described above. Cell nuclei were 
counterstained with DAPI, and sections observed by 
fluorescence microscopy.
In vitro angiogenesis and SMC recruitment 
assays
For in vitro angiogenesis assays, Matrigel (BD 
Biosciences, 356231) was coated onto 24-well culture 
plates and polymerized for 15 min at 37°C. HUVECs 
(1 × 105 cells/well) were seeded on Matrigel and 
incubated at 37°C for 12 h. To evaluate the effects of 
Cx40 inhibition on this process, similar experiments 
were conducted in presence of 300 µM 40Gap27 peptide 
[23, 25] or its scrambled version directly added to the 
growth medium. Capillary-like structures were observed 
and photographed through an inverted microscope Nikon 
TS100 (Nikon). Quantification of capillary-like structures 
was performed using the Angiogenesis analyzer plug-in 
on ImageJ software [26]. For SMC recruitment assays, the 
rat aortic VSMC line A7r5 obtained from American Type 
Culture Collection (ATCC; Manassas, VA, USA) was 
used. A7r5 cells were maintained in Dulbecco’s modified 
Eagle’s low glucose medium (DMEM; 31885–023, 
Life Technologies) supplemented with 10% fetal calf 
serum (FCS) and 1% penicillin/streptomycin at 37°C; 
5% CO2 and labeled with the PKH67 Green Fluorescent 
Cell Linker Kit (Sigma) according to manufacturer’s 
instructions. Fluorescent A7r5 cells (1 × 105 cells/well) 
were seeded into wells containing HUVECs capillary-
like structures generated under control conditions or after 
addition of 300 µM 40Gap27 peptide or its scrambled 
version to the media. Motility of SMCs was assessed by 
time-lapse microscopy using a Cytation3 Cell Imaging 
Multi-Mode Reader (BioTek). Images were acquired 
every 5 minutes over 6–8 hours. The quantification of 
SMC recruitment to capillary-like structures after 6 h was 
performed using ImageJ software.
Protein analysis
100 μg powder of s.c. B16-F10 tumors or 
confluent HUVECs collected from a 12-well plate 
were homogenized by sonication in SDS Lysis Buffer 
(62.5 mM Tris-EDTA, pH 6.8, 5% SDS). Protein 
content was measured using a detergent-compatible 
protein assay kit (Bio-Rad Laboratories, Reinach BL, 
Switzerland). 25 μg proteins were loaded on a 10% 
polyacrylamide gel, electrophoresed and transferred onto 
PVDF membrane (Immobilon-P; Millipore, Volketswil, 
Switzerland). Membranes were incubated for 1 h in TBS 
containing 5% milk and 0.1% Tween20 (blocking buffer). 
Saturated membranes were incubated overnight at 4°C 
with the following antibodies, against: Von Willebrand 
factor (Dako, A0082), diluted 1:2000; Phospho eNOS 
(PeNOS, Cell Signaling Technology, 9571), diluted 
1:1000; eNOS (BD Biosciences, 610297), diluted 1:1000; 
VEGFR2 (Cell Signaling Technology, 2479), diluted 
1:1000; MMP2 (Abcam, ab37150), diluted 1:1000; VE-
cadherin (Santa Cruz Biotechnology, sc-6458), diluted 
1:1000; smooth muscle actin (SMA, Abcam, ab5694) 
diluted 1:1000 or monoclonal antibody anti-alpha-
tubulin (T5168, Sigma-Aldrich, 1:3000). Membranes 
were then incubated at room temperature for 1 h with a 
convenient secondary antibody conjugated to horseradish 
peroxidase (FlukaChemie, diluted 1:20,000). Bands 
were developed using enhanced chemiluminescence 
(Millipore, Immunobilon Western Chemiluminescent 
HRP substrate), and visualized using a supercooled 
CCD camera (Chemidoc XRS, Bio-Rad Laboratories). 
Densitometric analysis was performed using ImageLab 
Software (3.0.1 Bio-Rad Laboratories).
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Statistical analysis
All tissue staining measurements were made 
using the ImageJ software (NIH Image, Bethesda, MD). 
Statistical analyses were performed using Prism 6.00 
for Windows (GraphPad software, San Diego, Ca). 
Differences between groups were performed by Mann-
Whitney test or by Student t test whichever applicable. 
Multiple comparisons were performed using one-way 
ANOVA and Tukey’s Multiple Comparison Test. Other 
statistical tests are indicated in the text or figure legends. 
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